Drugs / OTS-412
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07302945 | Jan 2022 | — | Bionoxx Inc. | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07170592 | Jan 2027 → Dec 2028 expected | refractory malignant neoplasm | Bionoxx Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07190833 | Mar 2026 → Dec 2028 expected | refractory malignant neoplasm | Bionoxx Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTS-412 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07190833 ↗ |
| Route | Intrathecal | “3×10E8 pfu, once q3 weeks, 3 cycles, IT” NCT07170592 ↗ |